Search Results - "Stahlie, Emma"

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC by Stahlie, Emma H. A., van Akkooi, Alexander C. J.

Get full text

External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort by Stahlie, Emma H. A., Carr, Michael J., Zager, Jonathan S., van Akkooi, Alexander C. J.

“…Purpose Talimogene Laherparepvec (T-VEC) is a modified herpes simplex virus type-1 used as intralesional immunotherapy in stage IIIB-IVM1a melanoma patients…”
Get full text

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model by Stahlie, Emma H. A., Franke, Viola, Zuur, Charlotte L., Klop, Willem M. C., van der Hiel, Bernies, Van de Wiel, Bart A., Wouters, Michel W. J. M., Schrage, Yvonne M., van Houdt, Winan J., van Akkooi, Alexander C. J.

“…Background Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for…”
Get full text

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience by Carr, Michael J., Sun, James, DePalo, Danielle, Rothermel, Luke D., Song, Yun, Straker, Richard J., Baecher, Kristin, Louie, Raphael J., Stahlie, Emma H. A., Wright, G. Paul, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Sarnaik, Amod A., Karakousis, Giorgos C., Lowe, Michael C., Delman, Keith A., van Akkooi, Alexander C. J., Ollila, David W., Collichio, Frances, Zager, Jonathan S.

“…Background Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for the treatment of unresectable, recurrent melanoma. The role of T-VEC after…”
Get full text

Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration by Walker, Richard J. B., Look Hong, Nicole J., Moncrieff, Marc, van Akkooi, Alexander C. J., Jost, Evan, Nessim, Carolyn, van Houdt, Winan J., Stahlie, Emma H. A., Seo, Chanhee, Quan, May Lynn, McKinnon, J. Gregory, Wright, Frances C., Mavros, Michail N.

“…Background Consideration of sentinel lymph node biopsy (SLNB) is recommended for patients with T1b melanomas and T1a melanomas with high-risk features;…”
Get full text

ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort by Stahlie, Emma H. A., Carr, Michael J., Zager, Jonathan S., van Akkooi, Alexander C. J.

Get full text

ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience by Carr, Michael J., Sun, James, DePalo, Danielle, Rothermel, Luke D., Song, Yun, Straker, Richard J., Baecher, Kristin, Louie, Raphael J., Stahlie, Emma H. A., Wright, G. Paul, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Sarnaik, Amod A., Karakousis, Giorgos C., Lowe, Michael C., Delman, Keith A., van Akkooi, Alexander C. J., Ollila, David W., Collichio, Frances, Zager, Jonathan S.

Get full text

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial by Rohaan, Maartje W., Stahlie, Emma H. A., Franke, Viola, Zijlker, Lisanne P., Wilgenhof, Sofie, van der Noort, Vincent, van Akkooi, Alexander C. J., Haanen, John B. A. G.

“…Abstract Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and…”
Get full text

Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma by Stahlie, Emma H A, Zijlker, Lisanne P, Wouters, Michel W J M, Schrage, Yvonne M, van Houdt, Winan J, van Akkooi, Alexander C J

“…We aimed to compare the relapse-free survival (RFS) in patients treated with adjuvant anti-programmed cell death-1 (anti-PD-1) therapy for a first diagnosis of…”
Get full text

Comment on “Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial” by Stahlie, Emma H. A., Blankenstein, Stephanie A., van Houdt, Winan J., Wouters, Michel W. J. M., van Akkooi, Alexander C. J.

Get full text

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis by Stahlie, Emma H.A., Mulder, Evalyn E.A.P., Reijers, Sophie, Balduzzi, Sara, Zuur, Charlotte L., Klop, Willem M.C., van der Hiel, Bernies, Van de Wiel, Bart A., Wouters, Michel W.J.M., Schrage, Yvonne M., van Houdt, Winan J., Grunhagen, Dirk J., van Akkooi, Alexander C.J.

“…Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and…”
Get full text

ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma—An International Multi-institutional Collaboration by Walker, Richard J. B., Look Hong, Nicole J., Moncrieff, Marc, van Akkooi, Alexander C. J., Jost, Evan, Nessim, Carolyn, van Houdt, Winan J., Stahlie, Emma H. A., Seo, Chanhee, Quan, May Lynn, McKinnon, J. Gregory, Wright, Frances C., Mavros, Michail N.

Get full text

The use of FDG‐PET/CT to detect early recurrence after resection of high‐risk stage III melanoma by Stahlie, Emma H. A., Hiel, Bernies, Stokkel, Marcel P. M., Schrage, Yvonne M., Houdt, Winan J., Wouters, Michel W., Akkooi, Alexander C. J.

“…Background The role of surveillance imaging in high‐risk stage III melanoma patients after complete surgical resection remains controversial, and with the…”
Get full text

Talimogene laherparepvec monotherapy for head and neck melanoma patients by Franke, Viola, Stahlie, Emma H.A., Klop, Willem M.C., Zuur, Charlotte L., Berger, Danique M.S., van der Hiel, Bernies, van de Wiel, Bart A., Wouters, Michel W.J.M., van Houdt, Winan J., van Akkooi, Alexander C.J.

“…Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, intralesionally administered in patients with stage IIIB/C-IVM1a unresectable…”
Get full text

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC) by Mulder, Evalyn E. A. P., Stahlie, Emma H. A., Verver, Daniëlle, Lemstra, Clara, Been, Lukas B., Mooyaart, Antien L., Brabander, Tessa, Vegt, Erik, Verburg, Frederik A., Veldt, Astrid A. M., Verhoef, Cornelis, Akkooi, Alexander C. J., Grünhagen, Dirk J.

“…Talimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment…”
Get full text

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma by Stahlie, Emma H. A., Blankenstein, Stephanie A., Houdt, Winan J., Wouters, Michel W. J. M., Akkooi, Alexander C. J.

Get full text

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective by Franke, Viola, Stahlie, Emma H.A., van der Hiel, Bernies, van de Wiel, Bart A., Wouters, Michel W.J.M., van Houdt, Winan J., van Akkooi, Alexander C.J.

“…Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a…”
Get full text

External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort by Stahlie, Emma H.A., Carr, Michael, Zager, Jonathan S., Van Akkooi, Alexander Christopher Jonathan

“…Abstract only 9563 Background: Talimogene Laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic…”
Get full text

Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial by Rohaan, Maartje W., Zijlker, Lisanne P., Stahlie, Emma H.A., Franke, Viola, Wilgenhof, Sofie, van der Noort, Vincent, Van Akkooi, Alexander Christopher Jonathan, Haanen, John B. A. G.

“…TPS9607 Background: The prognosis of patients with melanoma is significantly correlated with disease stage and has greatly improved with the introduction of…”
Get full text

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective by Franke, Viola, Stahlie, Emma H.A., van der Hiel, Bernies, van de Wiel, Bart A., Wouters, Michel W.J.M., van Houdt, Winan J., van Akkooi, Alexander C.J.

“…Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a…”
Get full text